PUBLISHED IN: 23-09-2026
In our last post we talked about adhesion — the dense, stuck-together scar-like tissue that forms in overused or underused muscle, and how it changes the way force moves through a joint. There's a second piece to that story that doesn't get talked about much outside research circles: a process called cellular senescence, and it turns out to be tangled up with adhesion in ways that are only now becoming clear.
Every cell in your body has a limited number of times it can divide before it hits a kind of internal stop sign. When a cell hits that limit — or gets damaged by injury, inflammation, or mechanical stress — it doesn't necessarily die. Instead, it can switch into a state called senescence: still alive, but permanently unable to divide. Researchers sometimes call these "zombie cells," and the nickname is more accurate than it sounds. A senescent cell doesn't just sit there quietly — it actively secretes a mix of inflammatory signals, enzymes, and growth factors, a cocktail researchers call the senescence-associated secretory phenotype (SASP), that spreads outward and affects the healthy tissue around it.
That secreted cocktail is where senescence and adhesion connect. SASP factors include enzymes that break down the existing structure of connective tissue, and signaling molecules — chiefly a growth factor called TGF-β — that push nearby cells to lay down excess, disorganized collagen in its place. A 2025 review in the journal Aging and Disease on tissue fibrosis and cellular senescence describes the result as a tissue environment that trades organized, flexible structure for dense, stiff, scar-like material — the same basic description as the adhesion we covered last time.
It also appears to run in both directions. Research on aging connective tissue shows that a stiffer, more fibrotic environment is itself a trigger that pushes nearby cells toward senescence, which then produces more of the same stiffening signals — a self-reinforcing loop rather than a one-time event. That helps explain why adhesion, once established, tends to get worse rather than better on its own: it isn't just old damage sitting there, it's an active process quietly recruiting more of itself over time.
This is where the practice's use of shockwave therapy becomes more than just a way to mechanically break up dense tissue. A 2024 systematic review in the International Journal of Molecular Sciences pulled together the signaling pathways shockwave therapy activates in fibrotic tissue, and the picture is more specific than "it loosens things up": shockwave pulses shift local immune cells (macrophages) from a pro-inflammatory state toward an anti-inflammatory, repair-oriented one; they reduce the excess collagen deposition associated with fibrosis; and they trigger programmed cell death in myofibroblasts — the overactive repair cells most responsible for laying down that excess collagen in the first place.
A 2023 study in the Journal of Orthopaedic Surgery and Research tested this directly on joint tissue: rats with immobilized knees developed joint capsule fibrosis, and shockwave treatment measurably reduced the abnormal collagen buildup and inflammatory markers driving it. Human data points the same direction — a 2024 clinical study in Skin Research and Technology followed 52 patients with dense post-surgical and post-injury fibrosis and found meaningful, measurable improvement in tissue texture and mobility after a course of shockwave sessions.
For a while, shockwave's antifibrotic effects and cellular senescence looked like two separate research threads that simply overlapped in theory. That changed with a study published in August 2025 in The American Journal of Sports Medicine, which looked specifically at knee osteoarthritis — the same joint-degeneration endpoint adhesion is ultimately linked to. Researchers examined subchondral bone (the layer of bone just beneath cartilage) across three models: tissue samples from knee OA patients, a rat model of induced arthritis, and lab-cultured osteoblasts (bone-building cells) put under inflammatory stress. Across all three, arthritic bone showed a clear rise in senescence markers — the same "zombie cell" signature described above — compared to healthy tissue.
The researchers then treated the arthritic rats and cultured cells with radial shockwave therapy at a carefully tuned dose, and senescence markers dropped substantially, alongside a measurable reduction in the abnormal, disorganized bone structure that senescent osteoblasts tend to leave behind. Notably, shockwave's effect held up against a proven benchmark: it performed comparably to regular treadmill exercise, one of the more well-established non-drug interventions for early knee osteoarthritis.
This doesn't mean shockwave reverses senescence everywhere in the body, or that it works identically on muscle and fascia adhesion as it does on subchondral bone in an arthritic knee — those are different tissues, and the research on each is at a different stage. But it's a direct, recent demonstration that shockwave's effects reach past collagen and local inflammation and down to the senescent cells driving joint tissue breakdown itself.
None of this changes what adhesion is or how it's treated day to day, but it does help explain why treating it works, at a level deeper than "loosening tight tissue." Adhesion isn't inert scar tissue that just sits there; it's maintained by an active cellular process that current research links to the same aging pathway responsible for a much broader set of age-related tissue changes — including, as the 2025 knee study shows, the joint degeneration that adhesion so often precedes. Shockwave therapy's well-documented antifibrotic effects — less collagen overproduction, more myofibroblast cleanup, calmer local inflammation, and now direct evidence of reduced cellular senescence in joint tissue — put it in a genuinely useful position for addressing more than one link in that chain at once.
Just west off I-25/Orchard in Greenwood Village/Denver Tech Center.